During the five-year collaboration, the partners will research disease-causing gene mutations and develop new CRISPR-based technologies for drug discovery.
Researchers from the Broad Institute and NIH characterized a CRISPR-associated transposase that can integrate DNA into unique sites in the E. coli genome.
ERS Genomics was founded to provide access to foundational CRISPR-Cas9 IP held by Emmanuelle Charpentier for applications other than human disease treatment.
In Genome Research this week: links between biological aging and mutations affecting epigenetic regulators; long-read sequencing-based strategy to map chromatin accessibility; and more.
